Cargando…

The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer

Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pop, Lucian, Suciu, Ioan Dumitru, Ionescu, Olivia, Ionescu, Paris, Toader, Oana Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/
https://www.ncbi.nlm.nih.gov/pubmed/32025249
http://dx.doi.org/10.25122/jml-2019-0115
_version_ 1783492999847608320
author Pop, Lucian
Suciu, Ioan Dumitru
Ionescu, Olivia
Ionescu, Paris
Toader, Oana Daniela
author_facet Pop, Lucian
Suciu, Ioan Dumitru
Ionescu, Olivia
Ionescu, Paris
Toader, Oana Daniela
author_sort Pop, Lucian
collection PubMed
description Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates.
format Online
Article
Text
id pubmed-6993292
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-69932922020-02-05 The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer Pop, Lucian Suciu, Ioan Dumitru Ionescu, Olivia Ionescu, Paris Toader, Oana Daniela J Med Life Review Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates. Carol Davila University Press 2019 /pmc/articles/PMC6993292/ /pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 Text en ©Carol Davila University Press This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review
Pop, Lucian
Suciu, Ioan Dumitru
Ionescu, Olivia
Ionescu, Paris
Toader, Oana Daniela
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title_full The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title_fullStr The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title_full_unstemmed The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title_short The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
title_sort dual blockade in the neoadjuvant setting of her-2 positive early-stage breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/
https://www.ncbi.nlm.nih.gov/pubmed/32025249
http://dx.doi.org/10.25122/jml-2019-0115
work_keys_str_mv AT poplucian thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT suciuioandumitru thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT ionescuolivia thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT ionescuparis thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT toaderoanadaniela thedualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT poplucian dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT suciuioandumitru dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT ionescuolivia dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT ionescuparis dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer
AT toaderoanadaniela dualblockadeintheneoadjuvantsettingofher2positiveearlystagebreastcancer